The VEGF modRNA was recently tested in a swine MI model (Carlsson et al, 2018) and type II diabetes patients (Gan et al, 2019), which highlighted the safety and efficacy of modRNA as a gene delivery tool. This evidence concerns the gene VEGFA and myocardial infarction.